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Regression Analysis 
&Lumen pre - post (Acute Gain) 
IVUS{4.78,~2.24mm 2) QCA{I.324.0.61mm) 
&Lumen post-6 mos R = 0.38 P - 0.002 R - 0.51 P = 0.0001 
AEEM (-0.79 4. 2.87 mm 2) R - 0.4 P = 0.0009 R = 0.28 P - 0.025 
&P+M(1.264.2.STmm 2, R=0.06 P-0.64 R=0.01 P=0.92 
• ',Lumen post - 6 mos {Late Loss) 
IVUS(-2.054.2.65mm 2) QCA(-0.56:E0.64mm) 
AEEM(-0.79:I:2.87mm 2) R-0.57 P-0.0001 R=0.38 P-0.0036 
AP+M(1.264.2.57mm 2) R=0.4 P-O.0011 R-0.32 P=0.009 
EEM = External Elastic Membrane, P + M = Plaque + Media 
Significant positive corretation between AG and LL was again deroon- 
sPated by beth IVU$ and QCA in this prospectiveN collected cohort of 
patients with high rate of follew-up study. Both &EEM and A P + M corre- 
lated well with LL However, AEEM but not A P + M correlated with AG. 
In conclusion, geometric remodeling but not changes in plaque volume was 
considered to be a generalized response to injury. 
~ D o e s  Coagulat ion Act ivat ion  Cause ReMenosis  in 
Pat ients Undergo ing  Direct ional  coronary  
Atherectomy?  
M. Lins, K. H, Zurbom, O. Dau, $. Muuding, G. Henmano, R. Simon. Dept. 
of Cardiology, University of Kiel, Germany 
Restenosis is a major problem of peroutaneous transluminal coronary an- 
gloplasty (PTCA) and related procedures. To better understand the under- 
lying pathophysio!ngic mechanisms, coagulation and fibrinolytic vodables 
were analysed prospectively in 36 pts after directional coronary atherectomy 
(OCA) and in 20 control pte undergoing diagnostic heart ,.:athetedzation and 
coronary angiography. Blood samples were taken before and 1 h, 24 h and 
48 h after the procedure. They revealed coagulation activation with a signifi- 
cant increase in proothrombin fragments (F1 + 2) from 0.75 to 0.97 nmoPl (P 
< 0.01) and throrobin-antithrombin III complexes {TAT) from 2.9 to 6 pg/l (P 
< 0,01) after 24 h. No significant changes were found in the control pts. No 
subecute thrombosis or unstable angina were documented in any pt. In 8 out 
of these 36 pte late restenosis (R+)was diagnosed dudng follow-up angiogra- 
phy 3-6 months after DCA. In these pts FI + 2 rose from 0.68 to 0,89 nmoPl 
(P < 0.01) and TAT from 3.2 to 4.7 pg/I (P < 0.01), but not significantly in 
pts without restenosis (R-). In pts with late restenosls plasminogen activator 
inhibitor (PAl-l) also increased from 2.4 to 4.9 U/ml (P < 0.05) 24 h after 
DCA white there were no significant changes in pta without restenosis and in 
control pts, O-Dlmer/rAT ratio indicating balance between dotting activation 
and tibdnotysis was significantly lower in restenosls pta after 24 h. 
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The findings suggest that coagulation activation and hypofibdnolysis during 
48 h after DCA could be risk factors for the development of late restenoals. 
• Relation Between Minimal Luminal Dimensions 
and Myocard ia l  Perfuaion Reserve Immediate ly  
After  Stent ing and  st  6 Months  Fo l low-up 
Michael Haude, Dietrich Baumgart, Guido Caspari, G0nter G6rge, 
Junbo Ge, Raimund Erbel. Cardiology Department, University Essen, 
Essen, Germany 
it has been shown that coronary flow velocity reserve as measured by 
intranoronary Doppler ultrasound and myocardial perfusion reserve (MPR) 
meesuled by X-ray densltometry can generally not be restored to normal 
values after coronary balloon angioptasty (PTCA). In order to evaluate the 
addifional impact of luminal widening (residual minimal luminal diameter 
(MLO) and cress-sectional area (MCA)) after coronary stenting on rnyocardia~ 
pedusion reserve we measured post-stanotio and reference MPR in 25 
patients with a proximal stenosis of the left anterior de~cen¢ling artery before 
PTCA, after PTCA (twice 10 atm for 30 s, I~llcon/artery ratio 1:1), after 
adjunct stenting (15 mm PS-Stent, 10 utm for 30 s, balloon/artery ratio 
1:1) and at 6 months follow up. Atl patients had no myocardial infarction, 
LV hypertrophy or diabetes. MPR was calculated as the ratio of baseline 
mean dee time (RT) and hyperemic (12 rag papaverine ic) RT, derived from 
densilometric evaluation of digital subtraction coronary angiegrama. 
Results 
Betore PTCA After PTCA After sterR At follow.up 
MLD[mm] 0.99:t:0.49 2.044.0.33# 3.15~:0.36 $ 2.18±0.57 +
MCAlmm 2] 0.97±0.74 3.35:E1.12# 7.87:t:1.72 $ 3.97:J:1.88 + 
Post-stanotic MPR 1.6 :J: 0.2 2.5:1: 0.8# 3.1 ± 0.5§ 2.8 ± 0.6 
Reference MPR 3.0 ± 0.3 3.0 ~ 0.3# 3.2 ± 0.3 3.0 ± 0.4 
ANOVA: #p < 0,01 remus before PTCA. §p < 0,05 versus after PTCA, Sip <: 0.01 versus 
after PTCA. +p < 0.01 versus after stenL 
There is a linear relation between MLD and post-stenotic MPR (MPR = 
0.52.MLD + 1.45; r = 0.87, SEE = 0.25) and a non-linear relation between 
MCA and post-stenotic MPR (MPR = -0.01-MCA 2 + 0.29-MCA + 1.72, r 
= 0.87, SEE = 0.25) during the intetventional procedure with restoration of 
post-stenotic MPR after stenting to normal reference levels. At 6 months both 
relations showed a steeper slope (MPR = 0.91.MLD + 0.67, r = 0.89, SEE 
= 0.23 and MPR = -0.04.MCA 2 + 0.57.MCA + 1.11, r = 0.87, SEE = 0.25) 
suggesting a long-term recovery of myocardial vascular capacity despite 
progressive luminal rananowing at the stanted vessel site. 
~ Ef fect iveness o f  Probucol  In Prevent ing  
Reetenosis  Af ter  Percutaneous "rransluminal  
Coronary  A( ,g icplacty:  Probucol  Ang iop lasW 
Rectanosis  Trial (PART) 
Hisashi Yokoi, Hireshi Yamaguchi, Yolchi Kuwabara 1 , for the PART Group. 
Juntendo Univora#y, Tokyo, Japan; 1 Chlba University, Chiba, Japan 
Oxidized low-density lipaprotein is an important activator that may play a 
role in etiological process for restenosis. Probucol has been known to have 
antioxidant properties as well as lipid lowering effect.. In animal models 
antioxidant therapy showed a beneficial effect on restenosis. Therefore, a 
prospective randomized control study was designed to clarify the prevP'~tive 
effect of Probucol on restenosis after PTCA. One hundred and one patients 
were randomly assigned for Probucol or control group by using minimization 
method. In Probucol group, 1000 mg of Probucol was administered daily 
4 weeks pdor to PTCA, and continued for observation period. In control 
group, no anti-hypedipidemic drug was administered. One PTCA region of 
interest per patient was specified at registration, and quantitative coronary 
ang/agraphy was performed before PTCA, soon and at least 16 weeks after 
PTCA. Restenosls was defined as a recurrent luminal stenosls of more than 
50% In the dilated segment at the time of restudy. Seventy eight patients 
(40 for Probucol and 38 for control) completed the study, and was used in 
the analysis. In Probucol group, mean total cholesterol level, low-density 
lipoproteln cholesterol level and high-densify Ilpoproteln cholasterot level 
decreased from 201 to 160, from 145 to 116, from 37 to 25 mg/di,respectlvety 
(p < 0.05 vs control). The results of QCA were as follows: 
Probucol Control 
Acute gala (ram) 1.14 4. 0.42 1,08 =1:0,54 n.s. 
Late loss (ram) 0.374.0.69 0.004.0.62 n,s. 
Net gain (ram) 0.774.0.70 0.48±0.59 p < 0.05 
Restenosis rate in Probucol group was 23% which was significantly lower 
than that in control group, 57% (p < 0.01). Multivariate analysis showed that 
this effect was independent of change in lipid level. 
In conclusion, Probucol administered 4 weeks prior to PTCA was effective 
in preventing restenosis after PTCA. 
